Blast Phase of Chronic Myeloid Leukemia (CML)
Olverembatinib, a third-generation BCR-ABL1 inhibitor with potent activity against the T315I mutation and compound mutations, has been approved in China at a 40 mg QOD schedule based on earlier phase I/II data.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025
- Chronic myeloid leukemia: Current guidelines for diagnosis and management
- Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment‑free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co‑primary endpoint
- Information about Project 4: Chronic myeloid leukemia (CML)
- Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia